Neuen BL, Young T, Heerspink HJL, et al. - In a systematic review and meta-analysis of randomized, controlled, cardiovascular or kidney outcome trials of sodium-glucose co-transporter-2 (SGLT2) inhibitors, experts evaluated the impacts of SGLT2 inhibitors on major kidney outcomes in patients with T2DM and to ascertain the consistency of impact size across trials and various levels of eGFR and albuminuria. From 2,085 records cataloged (n = 38,723 participants), four studies met the inclusion criteria, evaluating three SGLT2 inhibitors ie, empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS Program and CREDENCE), and dapagliflozin (DECLARE–TIMI 58). In individuals with T2DM, SGLT2 inhibitors decreased the risk of dialysis, transplantation, or death because of kidney disease and gave security against acute kidney injury. Thus, the data gives substantive proof establishing the use of SGLT2 inhibitors in order to prevent major kidney outcomes in individuals with T2DM.